A JAK2-positive essential thrombocythemia revealed by a brainstem ischemic stroke: A case report

Abstract

Essential thrombocythemia (ET) is a rare yet notable risk factor for ischemic stroke. Early detection and effective management of ET play pivotal roles in preventing stroke recurrence. Antithrombotic therapy is based on low-dose aspirin for ET patients with higher risk, and those with Janus Kinase 2 (JAK2) mutation. The present case reports a 68-year-old man presenting with ataxia, acute vertigo and dysphagia consistent with Wallenberg syndrome due to brainstem ischemic stroke. Laboratory analysis revealed elevated platelet and leukocyte counts. A positive JAK2 mutation examination and bone marrow biopsy confirmed the diagnosis of ET. Notably, these cerebrovascular events were the first manifestations of ET. This case underscores the need for careful screening of complete blood counts in patients with ischemic stroke, as early recognition and management of the underlying ET can significantly impact patient outcomes.